Spotlight On... Recipharm looks to close a $105M deal; Analyst says biotech slump won't affect CROs; and much more...

Swedish contract drugmaker Recipharm raised SEK 276 million ($32.5 million) to help close its pending acquisition of an Indian contract manufacturer. Through the sale of Class B shares, Recipharm now has the capital it needs to take up a 74% stake in Nitin Lifesciences, looking to wrap up a November agreement to buy a controlling share of the company for SEK 872 million ($105.2 million). Story

> Investors worried about whether the decline in biotech valuations will affect CROs should just sit tight, according to Wells Fargo analyst Tim Evans. More

> French CDMO Amatsigroup bought Belgium's Q-Biologicals for an undisclosed sum. News